Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The first quarter 10-Q is due 45 days after the end of the quarter (march 31) which would have been 5/14 but it is getting extended by SEC allowance 45 days until June 29. The 2019 10-K has all ready used up the 45 day extension and should come out this week (?)
It appears that the 10-K was delayed the 45 days and should come out this week and the 10-Q will be delayed the 45 days that the SEC allowed.
Strange to think that an investment fund is looking to get their money that they put into a company paid back by diluting the shares and driving the price further down. The last I checked investment funds/hedge funds actually what to make high returns on their investments.
It's easy to degrade Sabby as a toxic lender and a lender of last resort. However, Chris Lowe (who was touted as a financial expert and put together funding packages as CFO extraordinaire) was the one that turned to Sabby for $500,000.00 loan in July 2018 after he shut operations down just months before. It was that loan and loans after that that got NSPX SEC current, paid off some liabilities and kept things going. Sabby took the risk much more than anyone else.
It certainly would be lame if they miss the filing after the SEC gave a 45 day blanket time extension. The first quarter 10-Q may not come out but the 2019 10-K should.
I do expect that positive news will come some time in the future. This ticker has been quiet for sooo long that my expectation to the timing of positive news is limited to " I'll believe it when I see it". However, I will be looking for possible statements in the filings about the OS and if there is any mention of news with Ridgeway, MedicNova or Phyton.. NSPX has missed many filings in the past so first step is actually getting the filings submitted that are due so all can review them.
OPTION 6.. Forget first 5 and wait and see what happens to NSPX. Because at this point all are just guessing!
A hint.. it was a sweetheart deal between old buds Lowe and Flannery that probably has some caveats that are not posted. For $5000.00 he got the 5000 shares of preferred stock with voting rights of 30,001 votes each. Meaning he could rubber stamp everything Lowe wanted. Plus he got the conversion right to 1,000,000 common shares. Like most business it's not what you know it's who you know!
You would think that the cycle of borrowing money just to stay SEC current, maxing out AS and R/S and starting the cycle over again would get old but as long as there are investors willing to buy the stock it may continue. It's all very simple the drug platforms that everyone touts as valuable need to show their value to stop the cycle.
The website does have a page "contact us" where you can send a message. Don't expect a reply. I sent one when the web site was first updated months ago and have gotten no reply. IMO this stock is controlled by Sabby and they could care less about the anxious questions of shareholders. They will feed us SEC mandated filings and that's about it.
With no in house staff it's obvious that they outsource the management and administration of SEC filings. The 250K that Sabby loaned them in March should be enough to keep SEC current. The previous Sabby loans where stipulated for that purpose.
My last trade was 2/12 @.004. No reason for me to move on I've been following this ticker for a while and think Mipsagargin is going to be a valuable cancer drug in the future. Not worried at all about the little I have invested in this ticker.
I'm sure you have a trading plan that works for you. All I'm saying is that I know this ticker and it inflicts pure pain on investors. Everything you said.. not shareholder friendly, quiet for yrs, may miss filings etc. is basically true. can they r/s again..yes. can they raise the AS.. yes. However, If you think there may be value in what NSPX has.. endure the pain and hold your position or add. If you can't take it get out because there could be more pain to come!
Yes it looks like it's time for some to move on.. NSPX 15 minutes of fame may be ending and enduring the slide back to old lows could be too much to handle. Getting out and not putting up with the pain associated with this ticker may be the smart thing to do. There is money to be made elsewhere so why put up with dead money. Close out your positions, take the lumps and move on!
As posted by others. it was a total hype job that linked NSPX to remdesivir by the association of adenosine. This caused speculation that NSPX was also a candidate for a virus cure. When nothing came from the company to back up this speculation the PPS is returning to it's pre virus price. No big deal if you think that NSPX has future value the PPS doesn't mean much!
Yes it is a total gamble! However, the root reason to be in this stock is that what it has may have value. At the present time the PPS is not expressing that value. NSPX is waiting for the proper deal to materialize. While waiting they are spending as little as possible. Sabby is funding with loans to pay only necessary liabilities (SEC compliance etc) and keeping them alive. Sabby sees value ahead and is waiting. Investors are gambling that there is value ahead and are waiting. Everyone is waiting for something to happen.
Even going back to the Genspera days this was never an "operational co." as envisioned by most. It never had more than a few employees, never had their own lab and outsourced most/all of the administration, compliance and research responsibilities. Dr. Dionne worked out of small office in a bldg in San Antonio. Nspx never had an office and the address of the co. is their attorneys. They merged with L&C to obtain the Adenosine research and then shut L&C down. Their "operation" is to market the IP, patents and have others continue the research of both Genspera and L&C while the interest in the drug platforms grow.
This is why MedicNova chose Mipsagargin to be included in the updated patent application for its clinical trial for brain cancer.
"Initial indications that mipsagargin is well-tolerated and has some activity in glioblastoma are encouraging," said David Piccioni, M.D., Ph.D. at UC San Diego. "We look forward to expanding on this research and potentially bringing about an important new therapy for people with this aggressive disease."
In MedicNova's April 20,2020 press release the new patent application builds on an existing patent and names mipsagargin and other drugs as possible combination therapies for all types of glioblastoma. Ibudilast is already in a clinical trial and the new listed drugs could be incorporated in that trial. Although ibudilast has orphan drug status until 2039 it appears that MedicNova is moving fast to get this drug commercialized.
Listing mipsagargin in a patent is one thing .. using it in clinical trials and NDA (new drug application) is quite another. However, the fact that MedicNova listed mipsagargin in the patent is itself an indication that other pharma companies are interested in the IP and research of NSPX. If it comes to an FDA approved drug combination of mipsagargin and ibudilast a financial gain for the company would happen.
Don't overlook the fact that MedicNova listed mipsagargin as a investigative drug in the recent patent update. MediNovas drug MN-166 (ibudilast) is involved in numerous clinical trials and has orphan status for Glioblastoma. Mipsagargin has information about its clinical benefit from its own PH II trial for Glioblastoma. The combination of Mipsagargin as a front line drug to halt progression and MN-166 to administer the knock out punch would be a major advancement in the treatment for this disease.
Low volume retail trades.. meaningless! The chatter resembles Groundhogs day also meaningless..facts are all that matters!
You would think that some sort of agreement has been made with NSPX to use mipsagargin in a trial or study
Smart move! NSPX is resilient. Whether in the short run nothing new comes from the company.. what NSPX owns is real. Holding a good size stash of shares can be frustrating for sure but a positive event on either the Adenosine drug platform or the Mipsagargin platform may send this ticker to substantial highs. Nobody on this board knows when or if this is going to happen. I'M HOLDING JUST IN CASE IT DOES!
Low volume slide as dreams turn into nightmares. Moving down to the real load zone if peeps want to make serious cash! Wait and see!
It's just a surmise. The latest filings reported that 11.3 shares where os as of 12/1/19. The SC13 G/A filing 1/21 stated that Sabby and associated entities own 39.97% of the stock. Since 12/1 1,182,451,000 shares have been bought and sold. It is conceivable that the OS is approaching or at the AS of 150,000,000 shares. Using the same sabby % of ownership 60,000,000 shares is possible.
You never actually loose any money because money is just an object.. what you loose is the dream of what you could do with the money. If you have no dreams you have nothing to loose.
If you think making some chump change a lot on the last run .. fine. Sabby will probably make a lot if they end up with 40% of the AS (60 million shares) like they did in the last filing and then push the PPS into dollars like hedge funds liked to do.
This ticker is resilient.. it won't stay in nowhere land forever. What's the purpose of borrowing money to pay accountants and/or SEC just to stay current! They borrowed close to a million in the last 2 yrs to keep alive. I'm here to stay to see who makes a play for what they have and how much that play is worth. No sure thing but I'm a gambler.
My boats been loaded or I would jump in with you at these prices. I may be off base but I've always felt this is at least a $1.00 play or more. The facts are real the IP is real the patents are real.. no way the ticker lays dormant for too much longer. Way to many eyes on what it has to offer. How can any one justify the market cap at these prices.
can't get rid of shares at the ask.. got to sell to the bid if you want to get out of shares.
The million or so on the bid what in on this ticker!
The first r/s was 30 to 1 not 10 to 1! On 11/04 2016.
That would be nice but I don't expect Cain or anyone else associated with NSPX saying anything or do I expect any news coming out until it is ready to be announced. The filing might even be boilerplate as it has been in the past. I doubt that after 13 years of research, multiple patents, clinical trial results, orphan drug designations, and ongoing studies that this minuscule market cap will be the outcome of the ticker.
Assuming AS is maxed out.. with yesterdays close market cap 1.4 mil. Yea Right! Pick a big multiple of that and stick with it. Even at the most recent highs it would only be 5.5 mil. This ticker has a long upside ahead!
Be bold and hold!
Under Chris Lowe's miss management NSPX fell 6 SEC filings behind! The 500,000 debenture in July 2018 sabby enabled nspx to climb back to current with sec reporting as of last year. With the addition 250,000 reported in the 3/06 8-K the 10-K due mid march should not be a problem.
MM just cleaning house of weak hands..not to worry hold tight! Know what you own and be there when you need to be!
The inclusion of NSPX's drug mipsagargin in MediciNova's patent for treatment of Glioblastoma could development to be an important next step in the progress of the drug. It has always been thought that mipsagargin would be a first line treatment for brain cancer. Mipsagargin could hinder the progression of the disease, shrink the tumors or hold the cancer at bay until other treatments could be used. MediciNova's drug MN-166 (ibudilast) will be tested with a combination of various drug including mipsagargin. Genspera summarized their own trial #NCT02067156.
“We are very encouraged with the positive results from this interim Phase II trial that demonstrate the tolerability and indications of effectiveness of mipsagargin in advanced brain cancer patients,” said Craig Dionne, Ph.D., chief executive officer at GenSpera. “Mipsagargin is a first-in-class agent with a novel mechanism of action that is unlike any other drug being tested in patients with advanced brain cancer.”
NOT!!! Remdesivir is an FDA approved drug that is being tested currently! It is a adenosine analog! A tremendous stretch is that Nspx has a patent that they received from the merger with L&C that is unrelated to any approved drug that deals with adenosine. The only remote correlation would be a pharma co working with Nspx to try to get a drug similar to Remdesivir to market. It would take years! Although possible!
It didn’t bounce it rocketed off that 50 DMA! Good call!